<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: We evaluated the optimal dose of the <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> <z:chebi fb="0" ids="3347">candesartan</z:chebi> cilexetil for renoprotection as reflected by short-term changes in <z:mp ids='MP_0002871'>albuminuria</z:mp> in hypertensive type 2 diabetic patients with <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: A total of 23 hypertensive patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000112'>nephropathy</z:hpo> were enrolled in this double-blind randomized cross-over trial with four treatment periods, each lasting 2 months </plain></SENT>
<SENT sid="2" pm="."><plain>Each patient received placebo and <z:chebi fb="0" ids="3347">candesartan</z:chebi>: 8, 16, and 32 mg daily in random order </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="35674">Antihypertensive</z:chebi> medication was discontinued before enrollment, except for long-acting <z:chebi fb="0" ids="47426">furosemide</z:chebi>, which <z:hpo ids='HP_0000001'>all</z:hpo> patients received throughout the study in median (range) doses of 40 (30-160) mg daily </plain></SENT>
<SENT sid="4" pm="."><plain>End points were <z:mp ids='MP_0002871'>albuminuria</z:mp> (turbidimetry), 24-h blood pressure (BP) (Takeda-TM2420), and glomerular filtration rate (GFR) (<z:chebi fb="0" ids="50076">51Cr</z:chebi>-labeled EDTA plasma clearance technique) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Values obtained during placebo treatment: <z:mp ids='MP_0002871'>albuminuria</z:mp> [geometric mean (95% CI)] 700 (486-1,007) mg/24-h, 24-h BP (mean +/- SE) 147 +/- 4/78 +/- 2 mmHg, and GFR 84 +/- 6 ml/min/1.73 m2 </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> three doses of <z:chebi fb="0" ids="3347">candesartan</z:chebi> significantly reduced <z:mp ids='MP_0002871'>albuminuria</z:mp> and 24-h BP compared with placebo </plain></SENT>
<SENT sid="7" pm="."><plain>Mean (95% CI) reductions in <z:mp ids='MP_0002871'>albuminuria</z:mp> were 33% (21-43), 59% (52-65), and 52% (44-59) with increasing doses of <z:chebi fb="0" ids="3347">candesartan</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain><z:mp ids='MP_0002871'>Albuminuria</z:mp> was reduced significantly more by the two highest doses than by the lowest dose (P &lt; 0.01); 24-h systolic BP was reduced by 9 (2-16), 9 (2-16), and 13 (6-20) mmHg and 24-h diastolic BP was reduced by 5 (2-8), 4 (1-7), and 6 (3-9) mmHg with increasing doses of <z:chebi fb="0" ids="3347">candesartan</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>There were no significant differences in the reductions in BP between the three doses </plain></SENT>
<SENT sid="10" pm="."><plain>GFR was decreased by approximately 6 ml/min/1.73 m2 by <z:hpo ids='HP_0000001'>all</z:hpo> three doses of <z:chebi fb="0" ids="3347">candesartan</z:chebi> (P &lt; 0.05 versus placebo) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: The optimal dose of <z:chebi fb="0" ids="3347">candesartan</z:chebi> is 16 mg daily for renoprotection, as reflected by short-term reduction in <z:mp ids='MP_0002871'>albuminuria</z:mp>, in hypertensive type 2 diabetic patients with <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
</text></document>